For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06819007?term=GOG-3112&rank=1
GOG-3112: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DS8201-772/ENGOT-ov89/GEICO144-O)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gynecologic
Study Status:
Open to Accrual
Principal investigator:
Fong Liu, MD
IRB number :
2280060
Study Number:
G2502
Phone:
Fax:
GOG-3127: A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRa-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRa-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gynecologic
Study Status:
Open to Accrual
Principal investigator:
Fong Liu, MD
IRB number :
2407503
Study Number:
G2512
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07218809?term=trevi&viewType=Card&rank=2
GOG-3129: A Phase 2, Single-Arm Study of INCB123667 in Participants with Platinum-Resistant Ovarian Cancer with Cyclin E1 Overexpression (INCB123667-203)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gynecologic
Study Status:
Open to Accrual
Principal investigator:
Kimberly Levinson, MD
IRB number :
2373720
Study Number:
G2509
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07023627?term=GOG-3129&rank=1
GOG-3133: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer (FRAmework-01)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gynecologic
Study Status:
Open to Accrual
Principal investigator:
Fong Liu, MD
IRB number :
2442743
Study Number:
G2514
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07213804?term=j5e-mc-jzxb&viewType=Card&limit=10&sort=@relevance&rank=1
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Pulmonary
Study Status:
Open to Accrual
Principal investigator:
Mei Tang, MD
IRB number :
1384014
Study Number:
LUNGMAP
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT03851445?term=lungmap&rank=1